Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 13:48:59 UTC 2023
by
admin
on
Sat Dec 16 13:48:59 UTC 2023
|
| Protein Type | TRANSPORTER |
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
F202H3PMO2
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
816154-03-7
Created by
admin on Sat Dec 16 13:49:02 UTC 2023 , Edited by admin on Sat Dec 16 13:49:02 UTC 2023
|
PRIMARY | |||
|
F202H3PMO2
Created by
admin on Sat Dec 16 13:49:02 UTC 2023 , Edited by admin on Sat Dec 16 13:49:02 UTC 2023
|
PRIMARY | |||
|
Dopamine transporter
Created by
admin on Sat Dec 16 13:49:02 UTC 2023 , Edited by admin on Sat Dec 16 13:49:02 UTC 2023
|
PRIMARY | |||
|
Q01959
Created by
admin on Sat Dec 16 13:49:02 UTC 2023 , Edited by admin on Sat Dec 16 13:49:02 UTC 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_180 | 1_189 |
| 1_306 | 2_306 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_181 |
| N | 1_188 |
| N | 1_205 |
| N | 2_181 |
| N | 2_188 |
| N | 2_205 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
IN-VITRO
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
From Rat Membrane Studies
|
||
|
|
SUBSTRATE -> TRANSPORTER |
BINDING
IC50
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
Inhibition of [3H]Dopamine(100 uM) uptake in CHO cells expressing human dopamine transporter.
Ki
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR->OFF-TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER |
IN-VITRO
|
||
|
RADIOLIGAND->TARGET |
Ki
|
||
|
|
INHIBITOR -> TARGET | |||
|
RADIOLIGAND->TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IN-VITRO
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
|
RADIOLIGAND->TARGET |
Kd
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TRANSPORTER | |||
|
INHIBITOR -> TRANSPORTER |
|
||
|
INHIBITOR -> TARGET | |||
|
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Due to a risk of haemolytic anaemia, the U.S. Food and Drug Administration (FDA) withdrew approval for nomifensine on March 20, 1992. Nomifensine was subsequently withdrawn from the Canadian and UK markets as well.
BINDING
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
IN RAT
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
|
INHIBITOR -> TARGET |
BINDING
IC50
|
||
|
INHIBITOR -> TRANSPORTER |
|
||
|
LIGAND->TRANSPORTER | |||
|
|
INHIBITOR -> TARGET |
IC50
|
||
|
RADIOLIGAND->TARGET |
Binds to cocaine binding site of human dopamine transporter
|
||
|
|
INHIBITOR -> TARGET |
Ki
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT:NUMBER(CALCULATED) | CHEMICAL |
|